-
Je něco špatně v tomto záznamu ?
Panax notoginseng-Bletilla striata ameliorates reflux esophagitis by modulating NLRP3 inflammasomes and p38 MAPK pathway
X. Yang, T. Wu, H. Zhu, H. Ding, X. Chen, Q. Xu, H. Sun, G. Liang
Status minimální Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
NV18-09-00188
MZ0
CEP - Centrální evidence projektů
- Publikační typ
- časopisecké články MeSH
UNLABELLED: This study was to investigate the therapeutic effect of Panax notoginseng-Bletilla striata (PN-BS) in reflux esophagitis (RE) and its molecular mechanism. Using the '4.2 mm pyloric clamp + 2/3 fundoplication' method, a rat model of RE was developed. RE cell model was established by exposing HET-1 A (esophageal epithelial cells) to bile salt. Esophageal mucosal injury was observed by HE staining, and epithelial barrier dysfunction was assessed using Toluidine blue staining. HET-1 A cell viability was measured by CCK-8. Inflammatory factors in tissues and cells were detected by enzyme-linked immunosorbent assay. Claudin-4, Claudin-5, NLRP3, cleaved-caspase-1, p-p38 MAPK, and p38 MAPK protein levels were detected by Western blot. PN-BS attenuated esophageal mucosal injury and inflammation and improved esophageal barrier dysfunction in RE rats. Panax notoginseng saponins (PNS, the main active ingredient of PN) and Bletilla striata polysaccharides (BSP, the main active ingredient of BS) attenuated acid and bile salt-induced esophageal barrier dysfunction. PNS and BSP inhibited NLRP3 inflammasomes and p38 MAPK pathway activation. An inhibitor of NLRP3 inflammasomes (MCC950) or an inhibitor of the p38 MAPK pathway (SB203580) further enhanced the ameliorative effects of PNS and BSP. PN-BS reduces esophageal barrier dysfunction by inhibiting the activation of NLRP3 inflammasomes and p38 MAPK pathway, thereby improving RE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10616-025-00858-9.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25025790
- 003
- CZ-PrNML
- 005
- 20251212152536.0
- 007
- ta
- 008
- 251210s2026 xr f 000 0|eng||
- 024 7_
- $a 10.1007/s10616-025-00858-9 $2 doi
- 035 __
- $a (PubMed)41280658
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Yang, Xin $u Department of Spleen and Stomach Diseases, Suzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China $u Department of Traditional Chinese Medicine, Affiliated Hospital of Medical School, Suzhou Hospital, Nanjing University, Suzhou City, 215153 Jiangsu Province China
- 245 10
- $a Panax notoginseng-Bletilla striata ameliorates reflux esophagitis by modulating NLRP3 inflammasomes and p38 MAPK pathway / $c X. Yang, T. Wu, H. Zhu, H. Ding, X. Chen, Q. Xu, H. Sun, G. Liang
- 520 9_
- $a UNLABELLED: This study was to investigate the therapeutic effect of Panax notoginseng-Bletilla striata (PN-BS) in reflux esophagitis (RE) and its molecular mechanism. Using the '4.2 mm pyloric clamp + 2/3 fundoplication' method, a rat model of RE was developed. RE cell model was established by exposing HET-1 A (esophageal epithelial cells) to bile salt. Esophageal mucosal injury was observed by HE staining, and epithelial barrier dysfunction was assessed using Toluidine blue staining. HET-1 A cell viability was measured by CCK-8. Inflammatory factors in tissues and cells were detected by enzyme-linked immunosorbent assay. Claudin-4, Claudin-5, NLRP3, cleaved-caspase-1, p-p38 MAPK, and p38 MAPK protein levels were detected by Western blot. PN-BS attenuated esophageal mucosal injury and inflammation and improved esophageal barrier dysfunction in RE rats. Panax notoginseng saponins (PNS, the main active ingredient of PN) and Bletilla striata polysaccharides (BSP, the main active ingredient of BS) attenuated acid and bile salt-induced esophageal barrier dysfunction. PNS and BSP inhibited NLRP3 inflammasomes and p38 MAPK pathway activation. An inhibitor of NLRP3 inflammasomes (MCC950) or an inhibitor of the p38 MAPK pathway (SB203580) further enhanced the ameliorative effects of PNS and BSP. PN-BS reduces esophageal barrier dysfunction by inhibiting the activation of NLRP3 inflammasomes and p38 MAPK pathway, thereby improving RE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10616-025-00858-9.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Wu, TingTing $u Department of Spleen and Stomach Diseases, Suzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China
- 700 1_
- $a Zhu, HuiPing $u Department of Spleen and Stomach Diseases, Suzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China
- 700 1_
- $a Ding, HengYue $u Department of Spleen and Stomach Diseases, Suzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China
- 700 1_
- $a Chen, Xuan $u Department of Traditional Chinese Medicine, Affiliated Hospital of Medical School, Suzhou Hospital, Nanjing University, Suzhou City, 215153 Jiangsu Province China
- 700 1_
- $a Xu, QianFei $u Department of Spleen and Stomach Diseases, Suzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China $u Department of Gastroenterology and Hepatobiliary Medicine, Kunshan Hospital of Chinese Medicine, Suzhou City, 215300 Jiangsu Province China
- 700 1_
- $a Sun, HongWen $u Department of Spleen and Stomach Diseases, Suzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China $u Center Laboratory, Affiliated to Nanjing, Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China
- 700 1_
- $a Liang, GuoQiang $u Center Laboratory, Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Affiliated to Nanjing University of Chinese Medicine, Suzhou City, 215000 Jiangsu Province China $u Center Laboratory, Affiliated to Nanjing, Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, University of Chinese Medicine, No.889, Wuzhong West Road, Suzhou City, 215000 Jiangsu Province China
- 773 0_
- $w MED00007585 $t Cytotechnology $x 0920-9069 $g Roč. 78, č. 1 (2026), s. 3
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/41280658 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y -
- 990 __
- $a 20251210 $b ABA008
- 999 __
- $a min $b bmc $g 2446292 $s 1263988
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2026 $b 78 $c 1 $d 3 $e 20251119 $i 0920-9069 $m Cytotechnology $n Cytotechnology $x MED00007585
- GRA __
- $a NV18-09-00188 $p MZ0
- LZP __
- $a AZV-2022-Pubmed-20251210
